MARKER THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
MARKER THERAPEUTICS, INC. (MRKR) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $90.21 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-03-18
- MARKER THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2025 was $90.21K, a 225.52% increase from fiscal 2024.
- MARKER THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $27.71K.
- MARKER THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2018 was $24.37M.
- MARKER THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2017 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2025-12-31 | $90.21K 10-K · filed 2026-03-18 |
| 2024-12-31 | $27.71K 10-K · filed 2026-03-18 |
| 2018-12-31 | $24.37M 10-K · filed 2020-03-12 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |